Regulatory
Correction refers to change of category of press release from non-regulatory to regulatory. All other information is unchanged relative to previous version.
Non-regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that, following the national approval in Poland, the company has now received national market approvals in all 15 countries included in the Decentralised Procedure (DCP) approval receive…
Regulatory
Sales growth in our direct markets despite temporary market headwinds
Regulatory
According to the principles for the appointment of the Nomination Committee in Sedana Medical AB (publ), the Nomination Committee for the annual general meeting 2023 shall be composed of members appointed by the three largest shareholders as of Septe…
Non-regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announces that the company will hold a scientific symposium during ESICM Lives 2022, the annual congress of the European Society of Intensive Care Medicine. Additional data on inhaled sedation wil…
Non-regulatory
Sedana Medical AB (publ) plans to present its interim report for the third quarter 2022 in an audiocast on October 25 at 13.30 CET.
Non-regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announces that the company has received Medical Device Regulation (MDR) certification, which secures EU market access for Sedaconda® ACD under the new MDR regulation, well ahead of the deadline in…
Regulatory
Committed to change the standard of care, with commercial progress and a strong balance sheet.
Non-regulatory
Sedana Medical AB (publ) plans to present its interim report for the second quarter 2022 in an audiocast on July 21 at 13.30 CET.
Non-regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the UK's National Institute for Health and Care Excellence (NICE) has issued a Medtech innovation briefing (MIB) on the use of AnaConDa as an alternative to intravenous sedation in…
Regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that Susanne Andersson has been appointed new CFO and will take office during the first quarter of 2021. Susanne Andersson succeeds Maria Engström, who on her own initiative has chosen t…
Non-regulatory
Christer Ahlberg, CEO of Sedana Medical AB, has informed the company that he has sold 75 000 shares in Sedana Medical, representing approximately 0.33% of the total outstanding number of shares and 22.5% of his total shareholding in the company. Foll…
Regulatory
All-time-high sales and positive study result
Non-regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the company has signed a distribution agreement for sales in Australia and New Zeeland with the distributor Device Technologies. As the AnaConDa already has market approval in both…
Regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced a positive top line result for the company's pivotal phase III study, IsoConDa. The study reached its primary endpoint; to show that IsoConDa (isoflurane), administered with AnaConDa, is…
Non-regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the medical device AnaConDa has received market approval in Saudi Arabia and that the company has signed distribution agreements for sales in the Middle East with Techno Orbits in S…
Non-regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that it has signed agreements with distributors in Bulgaria, Cyprus, Greece, Slovakia and the Czech Republic. The agreements are part of the preparations ahead of the registration of the…
Non-regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that all warrants in the company's incentive program 2017/21 have been exercised by the warrant holders, leading to an increase in the number of shares and votes in the company by 310,14…
Regulatory
Today, May 19, 2020, the annual general meeting of Sedana Medical AB (publ) (”Sedana Medical” or the "Company") was held in Stockholm. The general meeting resolved to adopt all of the board of directors’ and the nomination committee’s resolution prop…